- CDC committee recommends adding COVID-19 to childhood vaccine schedule: The CDC’s Advisory Committee on Immunization Practices (ACIP), which makes guidance on vaccination policies, issued a report this week recommending that COVID-19 vaccines be added to the standard childhood immunization regimen. Under the new guidelines, most children ages six months and older should receive two doses of a Moderna or Pfizer vaccine, followed by a bivalent/Omicron-specific booster shot. Immunocompromised children are eligible for additional doses.
- KFF’s latest COVID-19 Vaccine Monitor focuses on winter surge: The Kaiser Family Foundation recently released the January 2023 update of its Vaccine Monitor project, which tracks U.S. sentiment around COVID-19 vaccines (and other pandemic topics) over time. In the latest round of surveys, KFF researchers found that about 38% of U.S. adults reported that “their households experienced either COVID-19, the flu, or RSV over the past month or so.” About 46% of adults reported that the news of these viruses made them more likely to take safety precautions. The report also includes data on bivalent booster shot uptake, behavior among immunocompromised people, and more.
- New variants have yet to emerge from China, study suggests: A new paper from researchers at the Beijing Center for Disease Prevention and Control, published in The Lancet this week, found that COVID-19 cases in China during November and December 2022 were primarily driven by the Omicron subvariants BA.5.2 and BF.7. Both of these lineages entered China from other countries, rather than evolving during the country’s surge following the end of its “zero COVID” policies. The new paper is good news for global health experts who’ve been worried about new variants emerging from China, though outside reviewers have cautioned that it’s only one small snapshot of cases in the country, according to reporting by POLITICO EU.
- Wastewater surveillance has a global health equity problem: Another study that caught my attention this week was a paper from the COVIDPoops19 team at the University of California Merced, summarizing findings from their global wastewater dashboard. The team reviewed wastewater surveillance projects at over 200 universities, 1,400 sites, and 55 countries, and found that monitoring primarily occurred in high-income countries. The researchers also examined open access to data, finding that high-income countries were better at sharing information with researchers and with the public. For wastewater-based epidemiology to reach its full potential, “show us the data,” the team writes in their paper’s abstract.
- Microbiome research shows promise for understanding ME/CFS: In one more piece of research news: two recent studies suggest that the gut microbiome could play a role in causing myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a debilitating chronic disease that often occurs after viral infection. In research projects funded by the National Institutes of Health, scientists found specific changes to gut bacteria that were associated with ME/CFS patients. These changes could potentially be used as biomarkers to diagnose ME/CFS and as starting points for treatment. The new research also has potential implications for Long COVID, as many Long COVID patients meet the diagnostic criteria for ME/CFS.
Tag: Featured sources
-
Sources and updates, February 12
-
Sources and updates, February 5
- CDC warns of risk to immunocompromised people: As of January 2023, there are no longer any monoclonal antibody treatments available for COVID-19, as these treatments do not provide protection against recent versions of Omicron. The no-longer-effective treatments include Evusheld, a drug used as a protective measure (to reduce risk of symptomatic COVID-19 for immunocompromised people. With Evusheld now unavailable, the CDC issued recommendations last week for people who have severely compromised immune systems. Of course, the CDC’s recommendations are largely targeted to individual action; to actually protet this vulnerable group, all Americans would need to follow collective public health measures.
- Modeling COVID-19 as a persistent “endemic“: A recent preprint, from researchers at the drug company Fractal Therapeutics and collaborators, estimates just how challenging it is for people to avoid COVID-19 when the disease is not managed at a societal level. The researchers estimated Americans’ long-term COVID-19 risk based on an epidemiological model incorporating frequent reinfections, and limited individual-level protections. People who are vaccinated but don’t take other measures to reduce their risk of getting COVID-19 “can expect to spend an average of 6 days a year acutely sick with COVID-19 and also incur a 12% risk of long COVID (symptoms lasting more than 3 months),” the researchers write.
- Global COVID-19 vaccination rate: Another new study, published in the CDC’s Morbidity and Mortality Weekly Report, provides an update on global vaccination rates, calculated by researchers at the World Health Organization. According to the WHO team, about 76% of older adults (ages 60 and older) have received a primary series of COVID-19 vaccines. (The study doesn’t report on booster rates, which are likely much lower worldwide.) As the vast majority of COVID-19 deaths worldwide have occurred among this age group, it should be a priority for vaccination, including the primary series and booster doses.
- COVID-19 litigation database: I recently learned about this database of COVID-related legal documents, run by researchers at the University of Trento in Italy. The database aims to publish case documents from around the world reflecting challenges to COVID-19 policies. As of February 4, it includes documents from 1,978 cases, which can be searched by country, year, type of human rights issue, vulnerable group involved, and more.
- Flu vaccine works well this year: A bit of non-COVID good news: this season’s flu vaccine is well-matched to the flu strain currently circulating in North America, according to a recent study from Canadian researchers and public health officials. Receiving a flu shot halved an individual’s risk of a severe flu case that needed medical care, the study found. Flu shots often have an effectiveness below 40%, explained STAT’s Helen Branswell on Twitter, as the vaccines do not always perfectly match up to circulating viral strains. But this year, the shot appears to be working well.
- NYC declares end of mpox epidemic: And one more bit of good news: New York City officials have declared that the city’s epidemic of mpox (formerly called monkeypox) is now over. The city was a hub for mpox transmission last summer and became a center of the U.S. outbreak; but NYC has reported low case numbers since early fall. The federal public health emergency for mpox also recently ended.
-
Sources and updates, January 29
- New York State expands wastewater surveillance program: This week, the New York State health department announced a major investment in the state’s wastewater surveillance program: the program has received a $6.6 million grant from the CDC and $15 million from the governor (over the next three years). With this investment, New York’s wastewater surveillance network will grow from 125 to 215 testing sites and will expand from COVID-19 to include flu, RSV, hepatitis, norovirus, and antimicrobial resistance. This is great news for New York—I hope to see other states make similar investments.
- Bivalent boosters vs. XBB lineages: The bivalent, Omicron-specific booster shots provide some protection against XBB.1.5 and related Omicron subvariants, according to a new study published this week in the CDC’s Morbidity and Mortality Weekly Report. CDC researchers used data from COVID-19 testing at pharmacies to compare results among people who had received the new booster and those who hadn’t. Booster recipients were significantly less likely to have a symptomatic XBB/XBB.1.5 infection compared to people who hadn’t received the shot, the researchers found (with a vaccine effectiveness value of 48%). While the boosters work less well against XBB.1.5 than they did against BA.4/BA.5, they’re still a valuable protective measure.
- CDC overhauling data communications: The CDC is creating new internal offices that will change how it processes, publishes, and communicates about data, according to POLITICO. The new offices include an Office of Health Equity and an Office of Public Health Data, Surveillance, and Technology—both of which have new acting directors as of this week. It’s currently unclear what the new offices will do, exactly, or how they will improve upon a fractured nationwide health data system (with decisions about how to store and share key data largely left up to state agencies and private companies). Still, it’s good to see movement on the CDC’s efforts.
- WHO deliberates ending the global health emergency: On Friday, a World Health Organization committee met to discuss whether the official global health emergency over COVID-19 should be ended. The committee’s decision will be made public tomorrow, as a recommendation to WHO Director-General Tedros Adhanom Ghebreyesus; Tedros will ultimately decide whether or not to end the emergency. Global health experts who spoke to STAT reporter Helen Branswell suggested that the WHO likely isn’t ready to end this emergency yet, but it may happen later in 2023.
- KFF compiles Long COVID data: A new report from the Kaiser Family Foundation compiles and provides context for Long COVID data reported by the Census and CDC’s Household Pulse Survey. The share of people who reported ever having Long COVID symptoms following a COVID-19 case has declined slightly over time, the KFF report finds; this number went from 35% in June 2022 to 28% in January 2023. However, the number is still high and Long COVID can be debilitating for many, as 79% of people with Long COVID report limitations to their day-to-day activities.
- Health of Congressional Districts: Finally: a new dashboard, published this week by researchers at NYU Langone Health, provides detailed health metrics for all 435 Congressional districts in the U.S. (plus Washington, D.C.). The dashboard is a helpful source for researchers and policymakers looking to understand health patterns in specific districts. One of its key metrics is a “COVID Local Risk Index” that reflects the risk residents face for severe health, social, and economic outcomes of COVID-19.
-
Sources and updates, January 22
- New CDC dashboards track respiratory illness hospitalizations: This week, the CDC released two new dashboards that combine COVID-19 data with data on other respiratory illnesses. First, the RESP-NET dashboard summarizes information from population-based hospital surveillance systems in 13 states for COVID-19, the flu, and RSV; it includes overall trends and demographic data. Second, the National Emergency Department Visits dashboard provides data on emergency department visits for COVID-19, the flu, RSV, and all three diseases combined; this dashboard includes data from all 50 states, though not all hospitals are covered.
- Early results from NIH at-home test self-reporting: Last week, ABC News shared early results from MakeMyTestCount.org, an online tool run by the National Institutes of Health allowing Americans to self-report their rapid, at-home test results. Between the site’s launch in late November and early January, “24,000 people have reported a test result to the site,” according to ABC. (While the article says “people have reported,” I think this number actually represents the number of test results reported, given that the website doesn’t track when one person submits multiple test results over time.) The majority of results reported are positive and women are more likely to self-report than men, per ABC. It’s unclear how useful these early data may be for any analysis, but I’m glad to see some numbers becoming public.
- New preprint updates county-level excess death estimates: A new preprint from Boston University demographer Andrew Stokes and colleagues, posted this week on medRxiv, shares updated estimates on excess deaths and COVID-19 deaths by U.S. county. According to the analysis, about 270,000 excess deaths were not officially attributed to COVID-19 during the first two years of the pandemic, representing 24% of all excess deaths during that time. And the analysis reveals regional patterns: for example, in the South and in rural patterns, excess deaths were less likely to be officially attributed to COVID-19. For more context on these data, see MuckRock’s Uncounted project (which is a collaboration with Stokes and his team).
- Factors contributing to low bivalent booster uptake: Another notable paper from this week: results from a survey of Americans who were previously vaccinated about their reasons for receiving (or not receiving) a bivalent, Omicron-specific booster this fall, conducted by researchers at Duke University, Georgia Institute of Technology, and others. Among about 700 people who didn’t get the booster, their most common reasons were a lack of awareness that the respondent was eligible for this vaccine, a lack of awareness that the bivalent vaccine was widely available, and a perception that the respondent already had sufficient protection against COVID-19. This survey shows how governments at every level have failed to advertise the bivalent boosters, likely to dire results.
- More wastewater surveillance on airplanes: And one more notable paper: researchers at Bangor University tested wastewater from three international major airports in the U.K., including samples from airplanes and airport terminals. About 93% of the samples from airplanes were positive for SARS-CoV-2, while among the airport terminal samples, 100% at two airports were positive and 85% at the third airport were positive. Similar to the study from Malaysia I shared last week, this paper suggests that there’s a lot of COVID-19 going around on air travel—to put it mildly. The paper also adds more evidence that airplane/airport wastewater can be a useful source for future COVID-19 surveillance.
- Nursing home infections ran rampant early in the pandemic: A new report from the Health and Human Services Office of Inspector General examines how much COVID-19 spread through nursing homes in 2020. The report’s authors used Medicare data from about 15,000 nursing homes nationwide, identifying those with “extremely high infection rates” in spring and fall 2020. In more than 1,300 of these facilities, 75% or more of the Medicare patients had COVID-19 during these surges; the same facilities had way-above-average mortality rates. “These findings make clear that nursing homes in this country were not prepared for the sweeping health emergency that COVID-19 created,” the authors write in the report’s summary.
-
Sources and updates, January 8
- NIH launches at-home testing telehealth program: This week, the National Institutes of Health announced the first location for “Home Test to Treat,” a new program that will make it easier for people in vulnerable communities to receive Paxlovid after testing positive on at-home, rapid tests. The Biden administration first announced this program in September, but it’s formally launching now with Berks County, Pennsylvania as the first participating community. As Paxlovid shifts to a drug that must be privately purchased instead of provided for free by the federal government, more programs like this one will be needed to fill access gaps.
- Study estimates global Long COVID prevalence: A large team of researchers, led by population health scientists at the University of Washington, conducted an extensive review of Long COVID symptoms. The analysis used 54 prior studies and two medical record databases, incorporating data from 1.2 million people in total. Overall, about 6% of patients reported at least one class of Long COVID symptoms three months after their initial infections, with the vast majority of cases occurring in people who had mild acute cases. The study was published in JAMA in October, but gained attention this week thanks to an article that its leading authors wrote in The Conversation.
- China’s COVID-19 data are unreliable: It’s been about a month since China loosened its COVID-19 protocols in the wake of protests and contagious Omicron subvariants, and the country is now facing a massive surge—with as many as one million new cases a day according to some modeling estimates. Yet COVID-19 deaths reported in the country have been very low, fewer than five a day. This discrepancy suggests that China’s authorities are not correctly counting their COVID-19 deaths, while the country’s dismantled testing infrastructure has also led to less reliable case numbers. Officials from the World Health Organization have formally called on the country to “be more forthcoming with information” about its COVID-19 surge, reports Helen Branswell at STAT News.
- CDC testing airplane wastewater on flights from China: In response to surveillance concerns, the CDC is working to test wastewater on flights arriving from China in select U.S. airports. This method is, of course, more efficient than testing every single traveler from the country in the interest of identifying any new variants that might arise. (Though it’s worth noting that some experts are skeptical about the potential of new variants arising in China.) Scientists from Concentric, a company that works with the CDC on traveler surveillance, previously talked about plane wastewater testing during our interview in November.
- Race/ethnicity differences among child vaccination rates: Finally, a notable study in this week’s CDC Morbidity and Mortality Weekly Report: researchers at the CDC and collaborators examined vaccination rates among children ages five to 17 using data from the National Immunization Survey. They found vaccination coverage (with at least one dose) was highest among Asian children (at about 75%), followed by Hispanic or Latino children (49%), white children (45%), and Black children (43%). The researchers also noted differences among vaccination rates by other socioeconomic factors, and by parents’ mask-wearing habits.
-
Sources and updates, December 18
- Federal government opens up at-home test orders: The Biden administration has revived its program to mail out free COVID-19 at-home rapid tests, just in time for the holidays. Every household can now order four more tests. This feels pretty minimal (and late in the season) for a surge already overwhelming hospitals, but it’s better than nothing. Also, remember to report your results from these tests to the National Institutes of Health’s new portal!
- COVID-19 vaccines saved millions of lives: A new report from the Commonwealth Fund estimates the hospitalizations and deaths saved by two years of COVID-19 vaccines, in honor of the two-year anniversary of those shots first becoming available. About 80% of Americans have received at least one vaccine dose, the authors write, “with the cumulative effect of preventing more than 18 million additional hospitalizations and more than 3 million additional deaths.” The modeling data underlying this analysis are available for download.
- Congressional COVID-19 subcommittee issues final report: House Democrats on the Select Subcommittee on the Coronavirus Crisis recently released their final report, a 200-page document outlining how the U.S. should prepare for the next public health emergency. The report sums up information from three years of research and hearings, including some new findings from more recent investigations. It was released in time with the Subcommittee’s final hearing last Wednesday, which also focused on preparedness. Next year, the Republican-controlled House will have new COVID-19 priorities.
- Helix and CDC build multi-disease surveillance program: This week, leading viral surveillance company Helix announced that its partnership with the CDC has expanded to include sequencing other respiratory viruses, beyond COVID-19. The company will work with major health systems in Minnesota and Washington to track viral variants for the coronavirus, flu, RSV, and other pathogens—and will build infrastructure connecting that sequencing data to electronic health records. That second piece is particularly intriguing, as variant data usually aren’t connected back to health records in the U.S.
- State-level wastewater surveillance expansions: The University of Minnesota is working on a process to test wastewater for the coronavirus, flu, and RSV simultaneously, according to reporting by local outlet KARE11. A team of researchers at the university’s medical school currently test wastewater from 44 sewage treatment plants in Minnesota, and is working to broaden this work with grants from the CDC and state health department. Across the country, New Hampshire’s state health department has announced that it will start publishing results of its COVID-19 wastewater testing program online in the coming weeks. The New Hampshire program includes 14 plants across the state.
-
Sources and updates, December 4
- CDC awards $3 billion to improve public health infrastructure: The CDC announced this week that it has awarded state and local public health agencies a total of $3.2 billion to support hiring and training new workers, along with other infrastructure needs. The agency published a breakdown of all the agencies that received awards, although it has not included specific details on what funds will be used for in each place. Local reporters, if your health department received funding, this might be worth looking into!
- CDC expands wastewater testing for polio: Another notable CDC announcement this week: the agency is expanding its wastewater surveillance for polio to two new areas, Oakland County, Michigan and Philadelphia. Testing wastewater for polio is more complicated than testing it for the coronavirus, as STAT News’ Helen Branswell explains in this article; as a result, the CDC is expanding this surveillance in a more limited capacity than what it’s doing for other viruses, like monkeypox and the flu.
- Majority of COVID-19 deaths are now among vaccinated people: A new report from the Kaiser Family Foundation explains why more than 50% of COVID-19 deaths in the U.S. in recent months were among people who had received at least two vaccine doses. According to KFF, factors driving this trend include the rising share of Americans who are vaccinated, waning protection from initial doses, and low uptake of booster shots—particularly of the Omicron-specific boosters that provide better protection against newer variants. More reason to get the new booster if you haven’t yet!
- Paid sick leave correlates with higher vaccination rates: Speaking of vaccination: a new study from researchers at Drexel University and Boston University found that large U.S. cities with city-wide paid sick leave policies had higher vaccination rates than those without such policies. The correlation was particularly evident in neighborhoods with higher social vulnerability, the researchers found. Expanding paid sick leave could help reduce inequities in vaccination coverage, the paper’s authors recommend.
- No monoclonal antibody drugs are currently authorized in the U.S.: This week, the FDA announced that bebtelovimab, a monoclonal antibody made by Eli Lilly, is no longer authorized for COVID-19 treatments in the U.S. The drug was designed based on older versions of the Omicron variant and doesn’t perform well against BQ.1 and BQ.1.1, the sublineages that are currently causing the majority of new cases in the U.S. As a result, no monoclonal antibodies are currently authorized, though Paxlovid and other treatments are still available.
-
Sources and updates, November 13
- Updated booster doses by state: This week, the CDC started reporting how many people have received the bivalent, Omicron-specific boosters by state, including state-level data for several demographic groups (over age 5, over 12, over 18, and over 65). The numbers are low: Vermont and Washington, D.C. have the highest booster rates as of November 9, with 21% and 20% of their populations receiving the bivalent shots, respectively. In about half of states, less than 10% of the population has received an updated booster. (H/t Jason Salemi.)
- Additional data suggests new boosters work against BQs: Speaking of the updated booster shots, a recent preprint from researchers at Emory University, Stanford University, and the NIH found that the new boosters produced several times more neutralizing antibodies against subvariants BQ.1.1 and BA.2.75.2 compared to the older vaccines. This was a small lab study and hasn’t yet been peer-reviewed, but it follows similar evidence from other research suggesting that the new boosters do provide additional protection against the most concerning variants currently circulating in the U.S. (See last week’s post.) If you haven’t gotten a bivalent booster yet, now is a good time!
- More evidence that masks in schools prevent COVID-19 spread: Another notable new study this week, published in the New England Journal of Medicine: a group of researchers from Boston institutions examined the differences in COVID-19 case numbers between public school districts that kept mask requirements in place during spring 2022, and those that lifted their requirements upon a statewide policy change in February. Overall, ending required masking led to “an additional 44.9 COVID-19 cases per 1,000 students and staff” during the remainder of the semester, the researchers found. The study demonstrates that masks are still a useful public health strategy to reduce illness—and risk of Long COVID—in schools.
- Paxlovid may reduce Long COVID risk: When Paxlovid first became available earlier in the year, some Long COVID patients reported that the drug helped alleviate their symptoms. A new study from Ziyad Al-Aly and his team at the Veterans Affairs St. Louis healthcare system provides evidence behind the anecdotal reports, finding that veterans treated with Paxlovid had a 25% lower risk of long-term symptoms, based on their electronic health records. The study has received some criticism (and has not yet been peer-reviewed); to me, it provides motivation for actual clinical trials examining Paxlovid’s use for treating Long COVID. RECOVER is running one such trial, but it won’t start until early 2023.
- Estimating COVID-19 infections from wastewater: And one more study that caught my attention this week: researchers at the University of Florida used a modeling technique called a “mass balance equation” to estimate how many people in Gainseville, Florida were sick with COVID-19 based on the virus’ concentration in wastewater. Using about one year of wastewater data (May 2020 to May 2021), the researchers were able to accurately predict actual infections with an error of just 1%. Translating wastewater data into useful information for public health action has been a major challenge for the growing field, so I was glad to see this study providing a potentially-useful method.
-
Sources and updates, October 16
- New paper outlines the CDC’s COVID-19 data failures: A new study by researchers at Johns Hopkins and Stanford, published this week in PLOS One, outlines missing and poor-quality epidemiological data that hindered the U.S.’s response to COVID-19. The researchers reviewed hundreds of reports by the CDC and other health agencies, finding that public data couldn’t answer key questions ranging from how long immune system protection lasts after an infection to which occupations and settings face the highest COVID-19 risk. (H/t Amy Maxmen.)
- White House pushes for improvements to indoor air quality: This week, the White House hosted a summit event on indoor air quality while launching new resources to help building owners improve their air. The summit featured talks by government officials and leading experts, discussing why indoor air quality is important—especially in public facilities like schools—and providing recommendations. (For more details, see this Twitter thread by Jon Levy.) Biden officials are calling on building owners to participate in the “Clean Air in Buildings Challenge,” which includes bringing in more clean outdoor air and enhancing filtration. While these are important steps for health improvements, some experts would like to see the federal government go further by mandating clean air.
- Voters do actually support safety measures, poll shows: New polling data from the left-wing think tank Data for Progress suggests that, contrary to popular narratives, a majority of Americans understand that COVID-19 still poses risks and support safety measures. For example, 74% of likely voters support the federal government requiring schools and workplaces to improve indoor air quality, and 70% of likely voters understand that certain groups (disabled people, seniors, etc.) remain at high risk from COVID-19.
- New study demonstrates long-term risks of infection: Another notable new paper from this week: researchers in Scotland used health records and surveys to follow about 33,000 people who tested positive for COVID-19, compared to 63,000 who did not. The patients were all surveyed at six, 12, and 18 months post-infection; between the six- and 18-month surveys, about 6% of the cohort had not recovered while 42% reported only partial recovery. As one of the biggest studies to date that doesn’t rely solely on health records, this paper shows how Long COVID can be devastating long-term for patients.
- Further research backs up testing out of isolation: And one more study I wanted to highlight this week: researchers at the University of California San Francisco examined how long people remained contagious after a coronavirus infection. The study included over 60,000 people who were tested at community sites in San Francisco. Five days after symptoms started, the researchers found, about 80% of patients infected during the Omicron BA.1 period were still positive on rapid tests—suggesting that, as other studies have found in the past, five days is an inadequate isolation period. Rapid testing out of isolation is the way to go.
-
Sources and updates, October 2
- Johns Hopkins dashboard creator wins public service award: Lauren Gardner, an engineering professor at Johns Hopkins University, was recently awarded the 2022 Lasker-Bloomberg Public Service Award (a major prize in biomedical research) in recognition of her work on JHU’s global COVID-19 dashboard. This dashboard was one of the world’s first and most popular sources for tracking how the pandemic spread. Unlike many other projects, it has continued fairly consistently since early 2020, and continues to be a great resource for national and international data. Congratulations to Gardner and the other folks at JHU!
- CDC releases updated chronic disease and risk factor data: This week, the CDC published a new iteration of its Behavioral Risk Factor Surveillance System (BRFSS), a major data source providing information on chronic conditions, health behaviors, access to healthcare, and more. The surveillance system uses surveys of over 400,000 American adults, conducted annually in all 50 states and several territories. While these aren’t COVID-specific data, the datasets can be a really helpful source for examining populations more vulnerable to COVID-19 in different parts of the country.
- Increased respiratory illnesses in children: Another CDC update: researchers from the agency published a new study in the Morbidity and Mortality Weekly Report reporting increased cases of respiratory illness in kids this past summer. Strains of rhinovirus and enterovirus that haven’t circulated much in the last two years are back in 2022 and could cause problems this fall—especially as schools continue to operate in-person with relatively few public health measures—the CDC report suggests. For more context, see this recent newsletter by Katelyn Jetelina and Caitlin Rivers.
- Biobot and CDC expand wastewater tracking to monkeypox: Biobot, the leading COVID-19 wastewater surveillance company, is expanding its work with the CDC to include monkeypox surveillance. As part of the CDC’s National Wastewater Surveillance System (NWSS), Biobot will coordinate data collection and analysis for both COVID-19 and monkeypox through at least January 2023. “We hope this can demonstrate the flexibility and versatility of this technology for governments across the country,” Biobot president and cofounder Newsha Ghaeli said in a press release.
- Launch of the Data Liberation Project: This is not COVID- or even health-specific, but I wanted to give a quick shout-out to the Data Liberation Project, a new effort by Jeremy Singer-Vine (widely known in data journalism circles as the author of the Data Is Plural newsletter). The new project is “an initiative to identify, obtain, reformat, clean, document, publish, and disseminate government datasets of public interest.” I hope to see some COVID-19 datasets liberated through this project!
COVID-19 Data Dispatch 